Reported Standalone quarterly numbers for Bal Pharma are: Net Sales at Rs 74.70 crore in September 2024 down 19.07% from Rs. 92.30 crore in September 2023. Quarterly Net Profit at Rs. 1.21 crore in September 2024 down 24.24% from Rs. 1.60 crore in September 2023. EBITDA stands at Rs. 7.84 crore in September 2024 down 2.85% from Rs. 8.07 crore in September 2023.
Open FlipReported Standalone quarterly numbers for Parmax Pharma are: Net Sales at Rs 9.28 crore in September 2024 up 128.05% from Rs. 4.07 crore in September 2023. Quarterly Net Loss at Rs. 0.22 crore in September 2024 up 84.14% from Rs. 1.37 crore in September 2023. EBITDA stands at Rs. 0.31 crore in September 2024 up 140.79% from Rs. 0.76 crore in September 2023.
Open FlipBSE share price advanced over 4 percent in November 25 trade on introduction of futures and options (F&O) contracts for 43 stocks. The information was disclosed post market hours on November 22 by the exchange. BSE stock surged 4.5 percent to its intraday high of Rs 4,933 per share on the NSE. At around 12 pm, the stock quoted at Rs 4,845.70 apiece, up 2.66 percent.
Open Flip